双顺反子CD19/22 CAR-T细胞疗法治疗儿童难治性狼疮性肾炎
本研究纳入3例14-17岁难治性IV±III/V型狼疮性肾炎患儿,经氟达拉滨和环磷酰胺清淋后接受自体双顺反子CD19/22 CAR-T治疗。所有患儿3个月内达显著临床缓解,随访9-15个月维持无药缓解;2例发生1级细胞因子释放综合征,1例发生4级CRS合并HLH/TMA经联合治疗控制。
要点
- 双顺反子CD19/22 CAR-T可使儿童难治性狼疮性肾炎3个月内达显著临床缓解
- 随访9-15个月所有患儿维持无药SLE或LN缓解
- 需警惕4级CRS合并HLH/TMA,治疗前严格筛选患者
核心结论
- 双顺反子CD19/22 CAR-T疗法在儿童难治性狼疮性肾炎中诱导了持续缓解。
- 治疗可触发HLH/TMA等严重并发症,但经积极支持治疗可控。
研究设计与样本
- 临床研究纳入3例14-17岁难治性IV±III/V型狼疮性肾炎患儿,既往多种免疫抑制治疗失败。
- 患者接受氟达拉滨和环磷酰胺清淋后输注自体双顺反子CD19/22 CAR-T细胞。
主要发现
- 所有患儿3个月内达显著临床缓解,随访9-15个月维持无药SLE或LN缓解。
- 2例发生1级细胞因子释放综合征,1例发生4级CRS合并HLH和TMA。
- CAR-T输注后1周内达深度B细胞清除,外周B细胞重建平均时间89±32天。
- 重建B细胞以CD27阴性初始B细胞为主,记忆B细胞和CD38+CD20-浆母细胞极少。
临床怎么用
- CAR-T治疗前需 meticulous 患者筛选以降低严重并发症风险。
- 治疗后应监测CRS及HLH/TMA,必要时采用甲泼尼龙、依托泊苷和依库珠单抗联合治疗。
局限性
- 样本量仅3例,随访9-15个月,长期疗效与安全性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Systemic lupus erythematosus (SLE) is an autoimmune disease and approximately 40% of patients with SLE progress to lupus nephritis (LN). The treatment of refractory SLE and LN remains challenging. This clinical study aimed to evaluate the efficacy and safety of bicistronic-CD19/22 targeted chimeric antigen receptor T-cell (CAR-T) therapy in pediatric patients with refractory LN. METHODS: Three pediatric patients (aged 14-17 years) with refractory class IV ± III/V LN were enrolled in the study. These patients had previously failed multiple immunosuppressive therapies. Following lymphodepleting chemotherapy with fludarabine and cyclophosphamide, patients underwent autologous bicistronic-CD19/22 CAR-T therapy. Clinical responses were analyzed. RESULTS: All patients achieved significant clinical remission within 3 months. During the 9- to 15-month follow-up period, all patients were maintained drug-free SLE or LN remission. Two patients developed grade 1 cytokine release syndrome (CRS). Another patient experienced grade 4 CRS complicated by hemophagocytic lymphohistiocytosis (HLH) and thrombotic microangiopathy (TMA), which was controlled with combination therapy of methylprednisolone, etoposide, and eculizumab. Deep B-cell depletion was achieved within 1 week following CAR-T infusion. The mean time to peripheral B-cell reconstitution was 89 ± 32 days, with the reconstituted B-cell population predominantly composed of CD27-negative naïve B cells, only minimal numbers of memory B cells and CD38+CD20- plasmablasts. CONCLUSION: Bicistronic-CD19/22 CAR-T therapy has induced sustained remission in pediatric patients with refractory LN. Although the treatment triggered severe complications-HLH/TMA. These complications were manageable with aggressive supportive therapy, underscoring the importance of meticulous patient screening before CAR-T administration. This therapy offers a promising treatment strategy for refractory LN.
引用
- Mao Y, Shen W, Shen J, et al. Bicistronic-CD19/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis. Kidney Int Rep. 2025. PMID: 41541778. doi:10.1016/j.ekir.2025.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。